{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:17:19Z","timestamp":1758406639815,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jid.2017.09.026","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T05:01:09Z","timestamp":1516338069000},"page":"246-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increasing the Complement of\u00a0Therapeutic Options in Bullous\u00a0Pemphigoid"],"prefix":"10.1016","volume":"138","author":[{"given":"Carolyn J.","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-7918","authenticated-orcid":false,"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2017.09.026_bib1","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2017.09.026_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.09.026_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.09.026_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","article-title":"Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid","volume":"31","author":"Lin","year":"2012","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jid.2017.09.026_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2017.09.026_bib6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jid.2017.09.026_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2017.09.026_bib8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/TP.0000000000001804","article-title":"Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1s monoclonal antibody TNT009\u2014results from a randomized first-in-human phase 1 trial","volume":"101","author":"M\u00fchlbacher","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jid.2017.09.026_bib9","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1172\/JCI17891","article-title":"Role of different pathways of the complement cascade in experimental bullous pemphigoid","volume":"116","author":"Nelson","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2017.09.026_bib10","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J\u00a0Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17330269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17330269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:11:10Z","timestamp":1758301870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X17330269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0022202X17330269"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2017.09.026","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increasing the Complement of\u00a0Therapeutic Options in Bullous\u00a0Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.08.030","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}